https://biotechtv.com

BiotechTV | Bringing the Biotech Sector to LifeBiotechTV covers the biotechnology sector with news, stories, and educational videos.BiotechTV | Bringing the Biotech Sector to Life top of pageHomeQuick TakesAround KendallScience SpotlightBiotechTV UCompany NewsBright MindsShowsBiotech DirectBioVenture VoiCesBiotech CEO SisterhoodThe Studio at Kendall SquareOff-Target Effects with Matt GlineTech + ToursPlay VideoFacebookTwitterPinterestTumblrCopy LinkEmbed VideoLink CopiedTOP VIDEO:  6/5/26 - From the New York Stock Exchange, AstraZeneca CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and moreQuick TakesUpcoming Events​May 29 - June 2 - ASCO Annual Meeting | Chicago, IL ​​ June 4 - The Hive Grand Opening | Paris, France ​ June 11-14 - EHA2026 Congress | Stockholm, Sweden ​ September 2 - Pareto Securities Healthcare Conference | Stockholm, Sweden ​ September 29-30 - William Blair Biotech Conference | Chicago, IL ​ December 12-15 - ASH Annual Meeting | New Orleans, LA ​ Science Spotlight with Chloe Kirk AI News with Ryan Flinn 05/29/26 - What to watch for at #ASCO26. ​ ​03/18/26 - Evaluate's Orphan Drug Report is FREE for anyone to download now. ​ #sponsored03/17/26 - Nvidia is expanding its partnership with Roche to create the largest supercomputer in pharma. Join the BiotechTV mailing listEmail JoinThanks for subscribing!Latest VideosPlay VideoFacebookTwitterPinterestTumblrCopy LinkLink CopiedWeek in Review: With 'new FDA' signaling a potential U-turn for uniQure in Huntington's Disease, biotech had one of its best weeks of the year06/20/2026Play VideoFacebookTwitterPinterestTumblrCopy LinkLink Copied10x Genomics: Serge Saxonov reflects on 10 years of the Human Cell Atlas Project.Learn more about AteraSponsoredPlay VideoFacebookTwitterPinterestTumblrCopy LinkLink CopiedBioVenture VoiCes: Nextech's Thilo Schroeder describes how keeping a focus on precision oncology has produced a thrilling ride over his career06/15/2026Play VideoFacebookTwitterPinterestTumblrCopy LinkLink CopiedWeek in Review: Biotech's movers for the week of June 8th and a preview of the week ahead06/14/2026Play VideoFacebookTwitterPinterestTumblrCopy LinkEmbed VideoLink CopiedEHA 2026: Karyopharm is hoping to add two new indications for selinexor over the near term - they just presented the phase 3 for the first one, myelofibrosis06/13//2026Shows Around Kendall Square What's new at BiotechTV - from our founderPlay VideoPlay Video11:28SF Healthcare Week: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026Play VideoPlay Video08:19SF Healthcare Week: Alnylam CEO Yvonne Greenstreet discusses the launch of Amvuttra in ATTR-CM and the company's new 2030 ambitions | 01/13/26Play VideoPlay Video15:01SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?Play VideoPlay Video10:23Capricor CEO Linda Marbán discusses the eventful year the company had for its DMD treatment deramiocel, including the P3 HOPE-3 readout, and the regulatory filing and review ahead | 01/13/26Play VideoPlay Video11:55SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO | 01/16/25Play VideoPlay Video10:51SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetesPlay VideoPlay Video10:04SF Healthcare Week: CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled LB Pharma to IPO in a tough market last year | 01/15/26Play VideoPlay Video13:04Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week.2026 SF Healthcare WeekPlay VideoPlay Video13:17ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications | 05/31/26Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemotherapy, and he discusses the medicine's side effect profile. Plus, next steps for this treatment in pancreatic cancer and beyond.Play VideoPlay Video05:44ASCO 2026: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck | 05/31/26CEO Claire Mazumdar describes the ASCO data, and updates us on the phase 2/3 study, which is already in the phase 3 portion. Bicara hopes to use the study to eventually gain an accelerated approval.Play VideoPlay Video35:05ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs | 05/31/26The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.Play VideoPlay Video14:55ASCO 2026: Summit Therapeutics' Co-CEO and Chief Strategy Officer discuss the HARMONi-6 ASCO data release for the PD-1xVEGF bi-specific antibody Ivonescimab | 06/01/26Maky Zanganeh and Dave Gancarz share their take on the result, which at the topline showed that Ivonescimab plus chemo reduced the risk of death by 34% vs the PD-1 Tislelizumab plus chemo, and they are given the opportunity to respond to some of the pushback heard around McCormick Place.Play VideoPlay Video09:22ASCO 2026: Celcuity CEO Brian Sullivan discusses the late breaking data for the PAM inhibitor gedatolisib that was just presented at ASCO - doubled the likelihood of survival in HR+/HER2- breast | 06/02/26These data were for patients with the PIK3CA mutation. The median PFS for the gedatolisib triplet combo was 11.1 months versus 5.6 months, compared to alpelisib plus fulvestrant.Play VideoPlay Video15:58ASCO 2026: Immuneering presented an update of the P2 trial of its deep cyclic inhibitor of MEK in 1L pancreatic cancer at ASCO. CEO Ben Zeskind argues why competitor data should not overshadow this | 06/1/26He describes the data, which showed a 17.3 months median OS in 55 patients vs. 8.5 months for SoC, and descrbies why he believes the therapy has an ideal profile for first line patients. A phase three study is already active and accruing patients.Play VideoPlay Video03:24ASCO 2026: Known for its leadership in antibody-drug conjugates, Daiichi Sankyo's US CEO and new Head of Global R&D discuss ASCO data and investments it will be making throughout oncology | 06/01/26Ken Keller and John Tsai describe which other modalities besides ADCs that Daiichi thinks about, and cover ASCO and pipeline progress on Enhertu (Her2), Datroway (Trop2), the company's B7-H3.Play VideoPlay Video11:40ASCO 2026: Ascentage Pharma is currently in nine registration trials, four of which are global studies intended for FDA and EMA filings. The founder, Dajun Yang, discusses this work, and ASCO data | 05/31/26He describes how Ascentage, which is already commercializing two medicines in China, has been working on its global programs. Plus, an overview of ASCO data (3 oral presentations and 3 posters) on the BCR-ABL inhibitor olverembatinib, Bcl-2 inhibitor lisaftoclax, and MDM2-p53 inhibitor alrizomadlin (APG-115).#ASCO26Play VideoPlay Video07:02ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma | 12/8/25Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point.Play VideoPlay Video16:50ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I | 12/8/25He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.Play VideoPlay Video19:29ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation | 12/9/25Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.Play VideoPlay Video11:07ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cell. Plus, the future of dual antigen and in vivo CAR-Ts. | 12/6/25She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M.Play VideoPlay Video13:14ASH 2025: Kura Oncology CEO Troy Wilson discusses the recent approval of the company's menin inhibitor (KOMZIFTI) in R/R NPM1 mutated AML, and highlights ASH data in the front line setting | 12/8/25He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion.Play VideoPlay Video17:45ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis | 12/7/25He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.Play VideoPlay Video12:48ASH 2025: Aleta Biotherapeutics' Paul Rennert shares the company's first clinical data for its CAR-T cell engager program that is meant to increase the density of CD19 on B-cell malignancies. | 12/8/25He describes the data, and walks us through two different dosing strategies. Plus, the business case for this simple biologic, and thinking about other antigens and cancer types.Play VideoPlay Video10:13ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS | 12/72/25He describes how Rigel became focused on both on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.#ASH25Follow BiotechTV@BiotechTVBiotechTVBiotechTVHQ@BiotechTV@BiotechTVHQAlso look for unique social pages for BiotechTV U.SponsorsLearn more about our sponsorsSponsor Spotlight10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.   Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.Learn moreGet in TouchContributorsAdvertise: News coverage opportunities:Advertise@BiotechTV.comMediaOppty@BiotechTV.com​Amy BrownUnited Kingdom Area Chris GarabedianBioVenture VoiCesGeneral equiries and feedback:Info@BiotechTV.comBrad LoncarFounderRyan FlinnAI in BiotechJoin our mail listMatt GlineOff-Target EffectsChloe KirkScience CorrespondentDisclosures & PoliciesWassim LaroussiMarkets CorrespondentThank you for watching! 📺bottom of pageenen1782114721https://biotechtv.com

ඔබේ අඩවිය සංස්කරණය කරන්නද?

ඔයා කරන්නේ කුමක් ද?